KRAS ‐G12D mutation drives immune suppression and the primary resistance of anti‐PD‐1/PD‐L1 immunotherapy in non‐small cell lung cancer
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
KRAS
‐G12D mutation drives immune suppression and the primary resistance of anti‐PD‐1/PD‐L1 immunotherapy in non‐small cell lung cancer
Authors
Keywords
-
Journal
Cancer Communications
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2022-07-11
DOI
10.1002/cac2.12327
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C–Mutant Non–Small Cell Lung Cancer
- (2021) Kathryn C. Arbour et al. CLINICAL CANCER RESEARCH
- CDK12 inhibition enhances sensitivity of HER2+ breast cancers to HER2-tyrosine kinase inhibitor via suppressing PI3K/AKT
- (2021) Hui Li et al. EUROPEAN JOURNAL OF CANCER
- Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint Inhibitor–Based Therapy in Patients With Advanced Non–Small-Cell Lung Cancer
- (2021) Lova Sun et al. JAMA Oncology
- Current and future drug combination strategies based on programmed death-1/programmed death-ligand 1 inhibitors in non-small cell lung cancer
- (2021) Ying Cheng et al. CHINESE MEDICAL JOURNAL
- SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition
- (2021) Joao V. Alessi et al. Journal of Thoracic Oncology
- Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer
- (2021) Marcelo V Negrao et al. Journal for ImmunoTherapy of Cancer
- Current Landscape of Non-Small Cell Lung Cancer: Epidemiology, Histological Classification, Targeted Therapies, and Immunotherapy
- (2021) Olga Rodak et al. Cancers
- Cancer incidence, mortality, and burden in China: a time‐trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020
- (2021) Haibo Qiu et al. Cancer Communications
- The efficacy and possible mechanisms of immune checkpoint inhibitors in treating non‐small cell lung cancer patients with epidermal growth factor receptor mutation
- (2021) Lin Ma et al. Cancer Communications
- RAS-targeted therapies: is the undruggable drugged?
- (2020) Amanda R. Moore et al. NATURE REVIEWS DRUG DISCOVERY
- KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
- (2020) David S. Hong et al. NEW ENGLAND JOURNAL OF MEDICINE
- KRAS G12V mutation upregulates PD‐L1 expression via TGF‐β/EMT signaling pathway in human non‐small‐cell lung cancer
- (2020) Li‐Na Pan et al. CELL BIOLOGY INTERNATIONAL
- KrasG12D mutation contributes to regulatory T cell conversion through activation of the MEK/ERK pathway in pancreatic cancer
- (2019) He Cheng et al. CANCER LETTERS
- KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition
- (2019) Helen Adderley et al. EBioMedicine
- Cancer-cell-secreted CXCL11 promoted CD8+ T cells infiltration through docetaxel-induced-release of HMGB1 in NSCLC
- (2019) Qun Gao et al. Journal for ImmunoTherapy of Cancer
- Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience
- (2019) Badi El Osta et al. Journal of Thoracic Oncology
- Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC)
- (2019) Arnaud Jeanson et al. Journal of Thoracic Oncology
- KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer
- (2019) Wenting Liao et al. CANCER CELL
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
- (2019) Tony S K Mok et al. LANCET
- Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment
- (2019) Narjust Duma et al. MAYO CLINIC PROCEEDINGS
- Biomarkers for immune checkpoint inhibition in non–small cell lung cancer (NSCLC)
- (2019) J. Nicholas Bodor et al. CANCER
- The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
- (2019) Jill Hallin et al. Cancer Discovery
- The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity
- (2019) Chengming Liu et al. CANCER LETTERS
- A Real-World Study in Advanced Non–Small Cell Lung Cancer with KRAS Mutations
- (2019) Lei Lei et al. Translational Oncology
- Feature specific quantile normalization enables cross-platform classification of molecular subtypes using gene expression data
- (2018) Jennifer M Franks et al. BIOINFORMATICS
- CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation – A target for novel cancer therapy
- (2018) Ryuma Tokunaga et al. CANCER TREATMENT REVIEWS
- Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer
- (2018) Suresh S. Ramalingam et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing
- (2018) Hira Rizvi et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of mutant variants of the KRAS gene on PD-L1 expression and on the immune microenvironment and association with clinical outcome in lung adenocarcinoma patients
- (2018) Alexander T. Falk et al. LUNG CANCER
- Cancer immunotherapy using checkpoint blockade
- (2018) Antoni Ribas et al. SCIENCE
- STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
- (2018) Ferdinandos Skoulidis et al. Cancer Discovery
- Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non–Small Cell Lung Carcinoma
- (2018) Chee Khoon Lee et al. JAMA Oncology
- A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
- (2018) Miguel F. Sanmamed et al. CELL
- Predictive biomarkers of response for immune checkpoint inhibitors in non–small-cell lung cancer
- (2018) Arsela Prelaj et al. EUROPEAN JOURNAL OF CANCER
- Nanoparticle albumin bound-paclitaxel for treatment of advanced non-small cell lung cancer: an evaluation of the clinical evidence
- (2018) Diego Adrianzen Herrera et al. EXPERT OPINION ON PHARMACOTHERAPY
- Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA
- (2017) Matthew A. Coelho et al. IMMUNITY
- Precision Diagnosis and Treatment for Advanced Non–Small-Cell Lung Cancer
- (2017) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies
- (2017) Emmet J. Jordan et al. Cancer Discovery
- STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment
- (2016) S. Koyama et al. CANCER RESEARCH
- Prognostic and Predictive Value inKRASin Non–Small-Cell Lung Cancer
- (2016) Kevin Wood et al. JAMA Oncology
- The 2015 World Health Organization Classification of Lung Tumors
- (2015) William D. Travis et al. Journal of Thoracic Oncology
- nCounter® PanCancer Immune Profiling Panel (NanoString Technologies, Inc., Seattle, WA)
- (2015) Alessandra Cesano Journal for ImmunoTherapy of Cancer
- First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
- (2014) Benjamin J. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap)
- (2013) S. Dearden et al. ANNALS OF ONCOLOGY
- Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome
- (2012) Nathan T. Ihle et al. JNCI-Journal of the National Cancer Institute
- Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer
- (2011) M. C. Garassino et al. ANNALS OF ONCOLOGY
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
- (2011) Caicun Zhou et al. LANCET ONCOLOGY
- Mammalian target of rapamycin complex 1: Signalling inputs, substrates and feedback mechanisms
- (2009) E.A. Dunlop et al. CELLULAR SIGNALLING
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now